Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement

Arthritis and Rheumatism

Volumn 64, Issue 5, 2012, Pages 1316-1322

  Wechalekar, Mihir D ^a   Lester, Susan ^b   Proudman, Susanna M ^b   Cleland, Leslie G ^b   Whittle, Samuel L ^b   Rischmueller, Maureen ^b   Hill, Catherine L ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT DISEASE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREVALENCE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SYNOVITIS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOOT JOINTS; HEALTH STATUS; HUMANS; HYPERALGESIA; MALE; MIDDLE AGED; PALPATION; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SYNOVITIS;

EID: 84860466443     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33506     Document Type: Article

References (38)

1. Wolfe FE, Hawley DJ,. The long-term outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients J Rheumatol 1998; 25: 2108-17.
2. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
3. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al, on behalf of the Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
4. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815-22.
5. Fransen J, Moens HB, Speyer I, van Riel PL,. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-8.
6. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
7. Fransen J, van Riel PL,. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S93-9.
8. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
9. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
10. Aletaha D, Smolen J,. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: S100-8.
11. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 2016-24.
12. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
13. O'Dell JR, Mikuls TR,. To improve outcomes we must define and measure them: toward defining remission in rheumatoid arthritis [editorial]. Arthritis Rheum 2011; 63: 587-9.
14. Dixey J, Solymossy C, Young A, and the Early RA Study. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004; 69: 48-54.
15. Ostendorf B, Scherer A, Modder U, Schneider M,. Diagnostic value of magnetic resonance imaging of the forefeet in early rheumatoid arthritis when findings on imaging of the metacarpophalangeal joints of the hands remain normal. Arthritis Rheum 2004; 50: 2094-102.
16. Sokka T, Pincus T,. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
17. Landewe R, van der Heijde D, van der Linden S, Boers M,. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006; 65: 637-41.
18. Combe B,. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 59-69.
19. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 36-41.
20. Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007; 37: 99-111.
21. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS,. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
22. Abramson JH,. WinPepi (PEPI-for-Windows): computer programs for epidemiologists. Epidemiologic perspective and innovations. 1:6 ed. Jerusalem: Hebrew University School of Public Health and Community Medicine; 2004.
23. Zeileis A, Kleiber C, Jackman S,. Regression models for count data in R. J Stat Software 2008; 27: 1-25.
24. R Development Core Team. R: a language and environment for statistical computing. R version 2.12.1. Vienna: R Foundation for Statistical Computing; 2010.
25. Jackman S,. Classes and methods for R developed in the Political Science Computational Laboratory, Stanford University. R package version 1.03.6 ed. Stanford (CA): Stanford University Department of Political Science; 2010.
26. Shammas RM, Ranganath VK, Paulus HE,. Remission in rheumatoid arthritis. Curr Rheumatol Rep 2010; 12: 355-62.
27. Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E,. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010; 49: 683-90.
28. Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland M,. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010; 37: 285-90.
29. Mease PJ,. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol 2010; 37: 1570-8.
30. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. Arthritis Rheum 2005; 52: 1020-30.
31. Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB,. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
32. Makinen H, Kautiainen H, Hannonen P, Sokka T,. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 1410-3.
33. Sesin CA, Bingham CO III,. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005; 35: 185-96.
34. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA,. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 36-42.
35. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011; 13: R83.
36. Van der Leeden M, Steultjens MP, van Schaardenburg D, Dekker J,. Forefoot disease activity in rheumatoid arthritis patients in remission: results of a cohort study. Arthritis Res Ther 2010; 12: R3.
37. Kapral T, Dernoschnig F, Machold KP, Stamm T, Schoels M, Smolen JS, et al. Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther 2007; 9: R72.
38. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011; 63: 3204-15.